Wiki · Profile

Tesamorelin

Egrifta · TH9507

GH SecretagogueApproved

MW: 5136g/mol
Formula: C221H366N72O67S

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that was approved by the U.S. Food and Drug Administration for the reduction of excess abdominal fat in individuals with HIV-associated lipodystrophy. Researchers primarily study tesamorelin for its effects on body composition and metabolic parameters in this specific patient population. Key findings from clinical trials indicate that tesamorelin significantly reduces visceral fat and improves body fat distribution without exacerbating glycemic control among individuals on integrase inhibitor-based antiretroviral therapy. Despite its established use in HIV-related conditions, current research highlights a lack of robust evidence supporting its application in other therapeutic areas, particularly within orthopaedics and sports medicine. Ongoing studies aim to further elucidate the safety and efficacy of tesamorelin in diverse clinical contexts.

Chemical Profile

Chemical Structure

Formula	C221H366N72O67S
Molecular Weight	5136 g/mol
CAS Number	218949-48-5
PubChem CID	16137828

Half-Life

SCSubcutaneous

~4 hours

INIntranasal

Not applicable

POOral

Poor bioavailability

Subcutaneous administration is the primary route due to its effective bioavailability.

Mechanism

Mechanism of Action

Tesamorelin acts as a growth hormone-releasing hormone (GHRH) analogue, binding to GHRH receptors on pituitary cells, which stimulates the release of endogenous growth hormone (GH). This increase in GH subsequently activates the insulin-like growth factor 1 (IGF-1) signaling pathway, promoting lipolysis and reducing visceral adiposity, particularly in individuals with HIV-associated lipodystrophy. While the precise mechanisms of action and downstream effects are not fully understood, it is known that tesamorelin influences metabolic processes related to fat distribution and energy homeostasis.

Research

46 Research Publications

1,355

Total Citations

Human/RCT

2.5

Avg. Influence

2024

Latest

Sort

Filter

01Top

#01

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

HumanInfluence5.0

184

The study demonstrated that tesamorelin treatment for 26 weeks significantly decreased visceral adipose tissue and improved lipid profiles in HIV-infected patients.

2 mgsubcutaneous(human)daily2 mg once dailysubcutaneous(human)12 months2 mgsubcutaneous(human)daily2 mgsubcutaneous(human)daily2 mgsubcutaneous(human)daily2 mgsubcutaneous(human)daily1 or 2 mgsubcutaneous(human)daily2 mgsubcutaneous(human)daily2 mgsubcutaneous(human)daily

PubMed

02Top

#02

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

ReviewInfluence8.0

129

The study demonstrated that lifestyle modifications and careful management of antiretroviral therapies are essential for reducing cardiovascular risk in individuals living with HIV.

PubMed

03Top

#03

Growth hormone in the aging male.

ReviewInfluence6.0

109

Researchers observed that tesamorelin effectively restores normal GH pulsatility and selectively reduces visceral fat in aging men, although its impact on muscle strength and quality of life remains unclear.

PubMed

#04

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

HumanInfluence1.0

Researchers observed that tesamorelin treatment resulted in significant reductions in visceral fat and improvements in body image and lipid profiles in HIV patients over 52 weeks.

PubMed

#05

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Human

Researchers observed that tesamorelin significantly reduced both visceral and liver fat in HIV-infected patients over a 6-month treatment period.

PubMed

#06

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

HumanInfluence4.0

Researchers observed that tesamorelin significantly reduces visceral fat by approximately 18% in HIV-infected patients with central fat accumulation without significant side effects.

PubMed

#07

How to diagnose a lipodystrophy syndrome.

ReviewInfluence1.0

Researchers observed that tesamorelin is effective in managing metabolic syndrome in HIV patients, highlighting the need for tailored therapeutic approaches.

PubMed

#08

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

HumanInfluence5.0

Researchers observed that tesamorelin significantly reduced hepatic fat in HIV-infected patients with non-alcoholic fatty liver disease compared to placebo.

PubMed

#09

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

HumanInfluence1.0

The study demonstrated that tesamorelin was well tolerated and resulted in sustained reductions in visceral adipose tissue and triglycerides over 52 weeks in HIV patients.

PubMed

#10

Peptide Ligation at High Dilution via Reductive Diselenide-Selenoester Ligation.

In Vitro

Researchers observed that the reductive diselenide-selenoester ligation method enables efficient synthesis of tesamorelin and lipidated variants of proteins, enhancing access to challenging biomolecules.

PubMed

Safety

Safety & Handling

Research Gaps

No comprehensive human trials have been conducted to evaluate the efficacy and safety of tesamorelin in orthopaedic applications, leaving its potential benefits in this field largely unvalidated. Additionally, the long-term effects of tesamorelin on body composition and metabolic health in patients with HIV, particularly those on integrase inhibitors, remain unclear, as do the specific mechanisms by which tesamorelin influences tissue regeneration and metabolic processes.

Solubility

Tesamorelin is soluble in water and commonly reconstituted in bacteriostatic water for injection.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Approved by the FDA for the treatment of HIV-associated lipodystrophy. Not scheduled by the DEA.

🇦🇺AU

Data limited

🇬🇧UK

Data limited

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Publications per Year

43 total

Pricing

Price Comparison

BESTRetaOneLabsUS
10mg
$39.00
Price/mg
$3.90/mg
View
RetaOneLabsUS
20mg
$84.00
Price/mg
$4.20/mg
View
Welli LabsUS
10mg
$49.99
Price/mg
$5.00/mg
View
Soma ChemsUS
10mg
$49.99
Price/mg
$5.00/mg
View
Eternal PeptidesUS
10mg
$52.99
Price/mg
$5.30/mg
View

Vendor	Amount	Price	Price/mg	Link
BESTRetaOneLabsUS	10mg	$39.00	$3.90/mg	View
RetaOneLabsUS	20mg	$84.00	$4.20/mg	View
Welli LabsUS	10mg	$49.99	$5.00/mg	View
Soma ChemsUS	10mg	$49.99	$5.00/mg	View
Eternal PeptidesUS	10mg	$52.99	$5.30/mg	View

Top 5 of 51 offers from 54 vendors. Prices updated daily.

See all Tesamorelin prices

Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for Tesamorelin

Serum Level Visualizer

Visualize Tesamorelin serum levels over time

Mechanism

Related Peptides

GHRP-2 Sermorelin MK-677 GHRP-6 Ipamorelin CJC-1295

Track Tesamorelin in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer